Shk Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 7 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.37 M
- Revenue Growth 36.62%
- Profit Growth -84.21%
- Ebitda -77.34%
- Net Worth 7.70%
- Total Assets -22.84%
About Shk Pharmaceuticals
Shk Pharmaceuticals Private Limited (SPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 04 August 2017 (Seven years and six months 22 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹0.37 M.
Ravi Matham and Rajeshwari H serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24304MH2017PTC298262
- Company No.
298262
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Aug 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Shk Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravi Matham  | Director | 16-Mar-2023 | Current |
| Rajeshwari H | Director | 16-Mar-2023 | Current |
Financial Performance of Shk Pharmaceuticals.
Shk Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 36.62% increase. The company also saw a substantial fall in profitability, with a 84.21% decrease in profit. The company's net worth moved up by a moderate rise of 7.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shk Pharmaceuticals?
Unlock access to Shk Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0.37 M
₹0
Charges Breakdown by Lending Institutions
- Uco Bank : 0.04 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Jan 2022 | Uco Bank | ₹0.37 M | Open |
How Many Employees Work at Shk Pharmaceuticals?
Unlock and access historical data on people associated with Shk Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shk Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shk Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
